View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 11, 2020updated 12 Jul 2022 11:45am

Namilumab and Infliximab selected for CATALYST trial in UK

The Universities of Birmingham and Oxford in the UK have partnered with Izana Bioscience and Celltrion Healthcare for the CATALYST clinical trial, which is assessing drug candidates to treat Covid-19 in hospitalised patients.

The Universities of Birmingham and Oxford in the UK have partnered with Izana Bioscience and Celltrion Healthcare for the CATALYST clinical trial, which is assessing drug candidates to treat Covid-19 in hospitalised patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

CATALYST is being performed in alliance with University Hospitals Birmingham NHS Foundation Trust (UHB) and the Birmingham National Institute for Health Research Biomedical Research Centre (NIHR BRC).

Izana Bioscience will provide its drug candidate, Namilumab (IZN-101), as the first of four potential treatments to be evaluate in the trial.

Namilumab is a fully human monoclonal antibody currently in late-stage trials for the treatment of rheumatoid arthritis and ankylosing spondylitis. It acts on granulocyte-macrophage colony stimulating factor (GM-CSF), which is naturally produced by immune cells in the body.

At abnormal levels, GM-CSF is believed to result in the excessive and dangerous lung inflammation observed in Covid-19 patients.

Celltrion Healthcare UK will provide its anti-tumour necrosis factor (TNF) therapy, Infliximab (CT-P13), which binds to a protein involved in inflammation.

Under the brand name Remsima, Infliximab is indicated to treat inflammatory conditions, including eight autoimmune diseases, such as rheumatoid arthritis and irritable bowel syndrome.

These drugs are expected to decrease the severity of the disease, reducing the number of patients being admitted to intensive care and virus-related deaths.

CATALYST trial co-clinical investigator Dr Ben Fisher said: “In the CATALYST study we hope to show with a single dose of these kinds of drugs in hospitalised patients that we are able to delay or prevent the rapid deterioration into intensive care and requirement for invasive ventilation in this critical patient group.

“We hope that by using a treatment that is already used to treat inflammation in other autoimmune conditions we may be able to manage inflammation associated with Covid-19 early.”

The trial is designed to enrol up to 40 patients to each arm. The effectiveness of each drug will be determined by the amount of oxygen in the blood and other disease severity indicators.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena